Mansoor Raza Mirza
Dept. of Oncology
Copenhagen University Hospital
Dr Mirza gained his degree in Medicine with honours in 1985, a Diploma in Surgery in 1986 and a Diploma in Clinical Oncology in 1988 from the Pirogov Moscow State Medical Institute. In 1994 he gained his License to practice medicine in Denmark (National Board of Health), in 1996 a Post graduation in Clinical Oncology from the University of Southern Denmark and his License to practice Medical & Radiation Oncology in Denmark (National Board of Health). His speciality is Medical and Radiation Oncology.
He is presently Chief Oncologist at the Dept. of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit (NSGO-CTU). He is also Vice-Chairman of the Danish Society of Gynaecologic Oncology (DGCG).
His key academic goals are to promote clinical research, international trial collaboration and education. He has broad experience in clinical protocol development, trial conduct and clinical trial regulations. He is author and principle investigator of several phase I, II and III studies and is chair/member of Independent Data Monitoring Committee (IDMC) of several international trials. He is senior author of national guidelines for the management of endometrial cancer, cervical cancer, vulvar cancer and nonepithelial ovarian cancer as well as NSGO radiotherapy guidelines for cervical and vulvar cancers.
Dr Mirza is actively involved within several Medical Societies: Chairman endometrial cancer Tumour-Site-Committee DGCG; Board of Directors: Gynaecologic Cancer Inter Group (GCIG), Founding Member: European Network of Gynaecological Oncological Trials Group (ENGOT), Board of Directors & Clinical Advisor: Karyopharm Therapeutics Inc. Boston, USA, Board of Directors: Metamark Genetics Inc. Boston, USA, Board of Directors: Sera Prognostics Inc. Salt Lake City, USA.
He is an ESMO Faculty Member, Member of the Danish Society of Clinical Oncology (DSKO); the European Society of Gynaecologic Oncology (ESGO), the International Gynaecologic Cancer Society (IGCS), the European Society of Therapeutic Radiology and Oncology (ESTRO), the Gynaecologic Oncology Group (GOG, USA) and the American Society of Clinical Oncology (ASCO).
Dr Mirza has participated in several GCP and Clinical Trials training.
He is reviewer of 4 peer review journals and author and co-authors of several articles in peer review publications.